Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $JANX
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/3/2024 | $82.00 → $100.00 | Buy | BTIG Research |
12/3/2024 | $63.00 → $70.00 | Buy | H.C. Wainwright |
11/22/2024 | $79.00 | Outperform | Leerink Partners |
10/24/2024 | $69.00 | Buy | UBS |
9/6/2024 | $70.00 | Buy | Stifel |
5/30/2024 | $47.00 | Sector Perform | Scotiabank |
3/21/2024 | $62.00 | Buy | BTIG Research |
3/20/2024 | $100.00 | Overweight | Cantor Fitzgerald |
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.
Clear Street Launches Healthcare & Biotechnology Equity Research
Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the closing of its previously announced underwritten public offering of 6,150,793 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 833,333 additional shares of common stock, at a public offering price of $63.00 per share and pre-funded warrants to purchase 238,095 shares of common stock at a price of $62.999 per pre-funded war
BTIG Research reiterated coverage on Janux Therapeutics with a new price target
BTIG Research reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $100.00 from $82.00 previously
H.C. Wainwright reiterated coverage on Janux Therapeutics with a new price target
H.C. Wainwright reiterated coverage of Janux Therapeutics with a rating of Buy and set a new price target of $70.00 from $63.00 previously
Leerink Partners initiated coverage on Janux Therapeutics with a new price target
Leerink Partners initiated coverage of Janux Therapeutics with a rating of Outperform and set a new price target of $79.00
Director Ra Capital Management, L.P. bought $53,700,000 worth of shares (1,200,000 units at $44.75) (SEC Form 4)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
Reardon Tighe bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
Lichter Jay bought $4,988,643 worth of shares (849,854 units at $5.87) (SEC Form 4)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
Chief Business Officer Meyer Andrew Hollman sold $140,999 worth of shares (3,334 units at $42.29) and exercised 3,334 shares at a strike of $4.21 (SEC Form 4)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
President and CEO Campbell David Alan sold $300,004 worth of shares (5,000 units at $60.00), decreasing direct ownership by 2% to 293,054 units (SEC Form 4)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
President and CEO Campbell David Alan was granted 81,000 shares, increasing direct ownership by 37% to 298,054 units (SEC Form 4)
4 - Janux Therapeutics, Inc. (0001817713) (Issuer)
SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.
SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
SEC Form SCHEDULE 13G filed by Janux Therapeutics Inc.
SCHEDULE 13G - Janux Therapeutics, Inc. (0001817713) (Subject)
SEC Form 8-K filed by Janux Therapeutics Inc.
8-K - Janux Therapeutics, Inc. (0001817713) (Filer)
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer. "The appointment of Zach to CMO is an important milestone for Janux. Zach's expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline," said David Campbell, Ph.D., President and CEO of Janux.
Janux Therapeutics Announces Updates to Board of Directors
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board member Ronald W. Barrett, Ph.D., as Chairperson Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Eric Dobmeier and Natasha Hernday to
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Tommy DiRaimondo to Chief Scientific Officer. "The appointment of Tommy to CSO is another important milestone for our company. Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our TRACTr and TRACIr platforms while supporting our clinical
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
Multiple patients treated with PSMA-TRACTr JANX007 have achieved meaningful PSA drops coupled with manageable safety and CRS PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008 have been generally well tolerated at levels above the projected maximum tolerable dose of the parental T cell engagers JANX007 preliminary data showed encouraging safety results consistent with on-tumor activity with no dose-limiting toxicities PK exposure demonstrated TRACTr activation with lack of TCE accumulation No treatment-emergent ADA titers observed Janux to host virtual investor event today at 4:00 PM Eastern Time Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutica
Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)
Amendment: SEC Form SC 13G/A filed by Janux Therapeutics Inc.
SC 13G/A - Janux Therapeutics, Inc. (0001817713) (Subject)